Positive News SentimentPositive NewsNASDAQ:ZLAB Zai Lab (ZLAB) Stock Price, News & Analysis $20.61 -0.96 (-4.45%) (As of 09/12/2024 ET) Add Compare Share Share Today's Range$20.51▼$21.2050-Day Range$16.25▼$21.5752-Week Range$13.48▼$31.22Volume800,409 shsAverage Volume626,939 shsMarket Capitalization$2.05 billionP/E RatioN/ADividend YieldN/APrice Target$58.97 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Zai Lab alerts: Email Address Zai Lab MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside186.1% Upside$58.97 Price TargetShort InterestBearish4.95% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.67Based on 3 Articles This WeekInsider TradingSelling Shares$975,291 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.95) to ($1.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.19 out of 5 starsMedical Sector554th out of 936 stocksPharmaceutical Preparations Industry251st out of 429 stocks 3.5 Analyst's Opinion Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZai Lab has only been the subject of 2 research reports in the past 90 days.Read more about Zai Lab's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.95% of the outstanding shares of Zai Lab have been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Zai Lab has recently increased by 4.67%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZLAB. Previous Next 3.2 News and Social Media Coverage News SentimentZai Lab has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Zai Lab this week, compared to 3 articles on an average week.Search Interest3 people have searched for ZLAB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $975,291.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zai Lab's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($2.95) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zai Lab's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. Go here to get full details on this crypto now. About Zai Lab Stock (NASDAQ:ZLAB)Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.Read More ZLAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZLAB Stock News HeadlinesAugust 20, 2024 | insidertrades.comInsider Selling: Zai Lab Limited (NASDAQ:ZLAB) Insider Sells 4,352 Shares of StockAugust 29, 2024 | insidermonkey.comZai Lab Limited (ZLAB): Top ADR Stock According to Hedge FundsSeptember 12, 2024 | Crypto 101 Media (Ad)The #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. August 18, 2024 | ca.finance.yahoo.comZLAB Sep 2024 17.500 putAugust 17, 2024 | finance.yahoo.comZai Lab Limited (NASDAQ:ZLAB) institutional owners may be pleased with recent gains after 25% loss over the past yearAugust 15, 2024 | markets.businessinsider.comZai Lab’s Solid Market Performance and Growth Prospects Justify Buy RatingAugust 13, 2024 | msn.com3 Small-Cap Stocks with Big Potential, Say Analysts (8/13/24)August 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zai Lab on Strong Financials and Promising Pipeline DevelopmentsSeptember 12, 2024 | Crypto 101 Media (Ad)The #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. August 8, 2024 | seekingalpha.comZai Lab Limited (ZLAB) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | markets.businessinsider.comWhat Wall Street expects from Zai Lab's earningsAugust 6, 2024 | finance.yahoo.comZai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate UpdatesJuly 26, 2024 | investorplace.comTrade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden GemJune 11, 2024 | businesswire.comZai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&DMay 22, 2024 | businesswire.comZai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque PsoriasisMay 20, 2024 | markets.businessinsider.comZai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+May 20, 2024 | businesswire.comZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in ChinaMay 17, 2024 | finance.yahoo.comInsider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells SharesSee More Headlines Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/12/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZLAB CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees2,175Year FoundedN/APrice Target and Rating Average Stock Price Target$58.97 High Stock Price Target$73.34 Low Stock Price Target$38.00 Potential Upside/Downside+181.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-334,620,000.00 Net Margins-92.44% Pretax Margin-92.44% Return on Equity-37.96% Return on Assets-29.42% Debt Debt-to-Equity RatioN/A Current Ratio3.46 Quick Ratio3.29 Sales & Book Value Annual Sales$322.71 million Price / Sales6.47 Cash FlowN/A Price / Cash FlowN/A Book Value$8.05 per share Price / Book2.60Miscellaneous Outstanding Shares99,609,000Free Float94,399,000Market Cap$2.09 billion OptionableOptionable Beta1.07 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Ying Du Ph.D. (Age 58)Founder, Chairperson & CEO Comp: $1.67MMr. Joshua L. Smiley (Age 54)President & COO Comp: $647.11kDr. Rafael G. Amado M.D. (Age 60)President and Head of Global Oncology Research & Development Comp: $477kDr. Harald Reinhart M.D. (Age 72)President and Head of Global Development for Neuroscience, Autoimmune & Infectious Diseases Comp: $923.33kDr. Yajing Chen Ph.D.Chief Financial OfficerDr. Peter Huang Ph.D.Chief Scientific OfficerMs. Christine ChiouSenior VP & Head of Investor RelationsMr. Frazor Titus Edmondson III (Age 58)J.D., Chief Legal Officer & Corporate Secretary Comp: $829kMs. Ann E. Beasley J.D.Chief Compliance OfficerDr. Ning Xu M.D. (Age 59)Executive VP & Head of Clinical Operations More ExecutivesKey CompetitorsIntra-Cellular TherapiesNASDAQ:ITCIElanco Animal HealthNYSE:ELANLantheusNASDAQ:LNTHRevolution MedicinesNASDAQ:RVMDAscendis Pharma A/SNASDAQ:ASNDView All CompetitorsInsiders & InstitutionsClearbridge Investments LLCSold 19,764 shares on 8/27/2024Ownership: 0.796%Joshua L SmileySold 4,352 sharesTotal: $72,547.84 ($16.67/share)The Manufacturers Life Insurance Company Bought 18,654 shares on 8/15/2024Ownership: 0.118%AXA S.A.Sold 9,126 shares on 8/15/2024Ownership: 0.066%DCF Advisers LLCBought 30,450 shares on 8/13/2024Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions ZLAB Stock Analysis - Frequently Asked Questions How have ZLAB shares performed this year? Zai Lab's stock was trading at $27.33 at the beginning of the year. Since then, ZLAB stock has decreased by 24.6% and is now trading at $20.61. View the best growth stocks for 2024 here. How were Zai Lab's earnings last quarter? Zai Lab Limited (NASDAQ:ZLAB) announced its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by $0.16. The firm had revenue of $100.50 million for the quarter, compared to analysts' expectations of $94.46 million. Zai Lab had a negative trailing twelve-month return on equity of 37.96% and a negative net margin of 92.44%. When did Zai Lab IPO? Zai Lab (ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO. Who are Zai Lab's major shareholders? Zai Lab's top institutional investors include Clearbridge Investments LLC (0.80%), M&G Plc (0.44%), Candriam S.C.A. (0.37%) and TD Asset Management Inc (0.22%). Insiders that own company stock include Ying Du, Harald Reinhart, William Lis, Joshua L Smiley, Frazor Titus Edmondson III, Yajing Chen, Peter Wirth, Tao Fu and John D Diekman. View institutional ownership trends. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI) and Marvell Technology (MRVL). This page (NASDAQ:ZLAB) was last updated on 9/12/2024 by MarketBeat.com Staff From Our PartnersWhat Kamala WON’T Do if she wins the electionA lot of folks have their fingers crossed about Kamala Harris winning the election… After all, she’s promis...Banyan Hill Publishing | SponsoredInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZLAB Stock Alerts